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Abstract
Obstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences,
including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving
ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic
syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the
assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most
studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other
therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term
management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at
the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which
are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term
management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms
and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve.
Keywords: Obstructive sleep apnea, Cardiovascular disease, Hypertension, Diabetes, Dislipemia, Long-term
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Introduction
We define obstructive sleep apnea (OSA) as an entity char-
acterized by repeated collapses of the pharynx during sleep
that reduce or eliminate airflow completely for at least 10 s
and in a number of 5 episodes or more every hour of sleep
(Apnea-Hipopnea Index, −AHI-). These episodes are associ-
ated with sympathetic activation, exaggerated negative
swings in intrathoracic pressure, intermittent oxyhemoglo-
bin desaturation, hypercapnia and arousal from sleep. These
physiological changes seem to act as intermediate mecha-
nisms responsible for the accelerated development of new
comorbidities. This topic has been reviewed extensively in
Multidisciplinary Respiratory Medicine by MR Bonsignore
et al. [1]. In this chapter we will review three relevant ques-
tions: 1) the available information on the natural history of
OSA and its relationship with incident comorbidities,
particularly cardiovascular ones, 2) how the available treat-
ment for patients with OSA does impact the evolution of
OSA and 3) how the OSA treatment can modify the health
outcomes of the comorbidities associated with OSA. Unfor-
tunately, there is little information in the literature on both
subjects. This is so, because since the appearance of con-
tinuous positive airway pressure (CPAP) as an effective treat-
ment to reverse OSA symptomatology, it would not be
ethical to study the natural history of symptomatic patients
with OSA for a long time of period without offering them
an effective treatment.
Clinical course of obstructive sleep apnea
OSA is actually part of a “continuous” patho-physiological
process in which the upper airway (UA), mainly the phar-
ynx, shows a high resistance to air flows (Fig. 1). Initially
this dysfunction is asymptomatic or manifested by snor-
ing: “stage of susceptibility”. Predisposed subjects probably
have a genetic load of susceptibility that we are largely un-
aware of. With adulthood and in parallel with weight gain,
environmental and epigenetic factors aggravate the col-
lapsibility of the UA. In this “pre-symptomatic” stage,
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snoring is usually aggravated, nocturnal apneas appear but
the subject may not report a diurnal limitation in his/her
activities. Without solution of continuity, the patient
evolves towards a “stage of clinical illness” in which mor-
bidities develop at younger ages with respect to the
non-OSA population in what we could consider in some
way an accelerated aging. If patients are not identified and
treated, the natural evolution is towards disability and pre-
mature death mainly due to cardiovascular events.
In current medicine, knowledge about the natural
evolution of diseases is based on the descriptions
made by doctors in the last century. It is not possible
with current treatments to validate these descriptions
through observational cohort studies and much less
with randomized controlled trials (RCT). In OSA it
happens the same thing. The first detailed descrip-
tions of OSA were made by European authors. How-
ever, these reports did not describe the long-term
evolution of the disease [2, 3]. Before the description
by Sullivan et al of the efficacy of CPAP for the treat-
ment of OSA [4], physicians who treated these pa-
tients only had upper airway surgery (including
tracheotomy). Early clinical descriptions of OSA in-
cluded substantial disability and health care
utilization, largely reflecting the limited management
options available at the time. Many patients evolved
towards the development of heart failure and respira-
tory failure or dying in various accidents. The major-
ity of these patients were young adults. In the last 30
years, many studies on the evolution and short- and
long-term management of OSA have been published.
We review here briefly the most significant studies
grouping them according to their study design: clin-
ical based cohort, community-based cohort and RCT
(Table 1).
Cohort studies
The first clinical-based and retrospective studies
seemed to indicate that patients with severe OSA
treated with tracheotomy and CPAP had better survival
than those treated with uvulo-palato-pharyngoplasty
(UPPP) or by conservative measures [5, 6]. Mortality
rates were around 6% per 5–8 years among the un-
treated patients, being cardiovascular events the most
frequents causes of death. What was interesting about
these early studies is that, despite their methodological
limitations, it appears that the “complete” suppression
of apneas/hypopneas with treatments such as tracheot-
omy or CPAP could improve the survival of patients
with OSA, while other “partial” efficacy techniques (e.g.
the UPPP) did not influence the health outcomes of the
patients, therefore cannot be recommended to treat the
most severe cases of OSA. There were another four
prospective studies with three of them only including
elderly population with contradictory results [7–10].
All six studies had many methodologic limitations be-
cause they failed adequately to take into account im-
portant confounding risk factors for cardiovascular
diseases, such as obesity, smoking, dyslipemia, or
hypertension. As stated in a systematic review pub-
lished in 1997 by Wright et al., the results of those
studies showed inconsistent results with limited evi-
dence to link OSA with an excess of mortality [11].
Fig. 1 Natural history of obstructive sleep apnea (see text for details)
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Since the Wright's paper was published, many well de-
signed longitudinal studies have confirmed increased
mortality in OSA patients. In Israel, Lavie and colleagues
collected mortality information among a very large co-
hort of 14,589 men referred to the sleep clinics with sus-
pected sleep apnea [12]. After a median follow up of 4.6
years, Cox proportional analysis revealed that both BMI
and RDI were independently associated with mortality.
Unfortunately, no other potential risk of mortality, clin-
ical status at diagnosis, or therapy was controlled. In
USA, among patients without pre-existing cardiovascu-
lar diseases who were referred to a Sleep Center for the
evaluation of sleep-disordered breathing, Yaggi and col-
leagues reported an increased risk for death or stroke in
OSA patients and a dose-effect relationship between
OSA severity and risk [13]. Unfortunately, use of nasal
CPAP was not evaluated and the short duration of fol-
low up (3 years) and the small number of observed
events did not allow the specific assessment of the ef-
fects of therapy. In 2005, we reported the long-term car-
diovascular outcomes in men with OSA referred to our
sleep unit between January 1, 1992, and December 31,
1994 [14]. During the recruitment period, 1,465 patients
had polysomnography and treatment with CPAP was
recommended to 667 patients. Patients attended the
clinic yearly. During these visits, compliance with CPAP
therapy was assessed by the timer built into each CPAP
device. A mean daily use of more than 4 h per day was
considered necessary to maintain the CPAP prescription.
After a mean of 10.1 years, Patients with untreated se-
vere OSA had a higher incidence rate of fatal events
(1.06 events per 100 person-years) than untreated pa-
tients with mild-moderate OSA (0.55 events, < 0.02);
simple snorers (0.34 events, p < .0005); patients treated
with nasal CPAP (0.35 events, p < .005); and healthy sub-
jects (0.3 events, p < .005). Multivariate analysis adjusted
for potential confounders showed that untreated severe
OSA increased significantly the risk of fatal cardiovascu-
lar events (odds ratio 2.87; 95% CI, 1.17–7.51) compared
with healthy subjects (Table 2). At the time, this study
was very relevant because it contributed not only to the
knowledge of the natural history of OSA, but also to es-
tablish AHI > 30 as a defining reference value for severe
OSA. It was also the first paper to report that CPAP
therapy reduces the risk of fatal and non-fatal cardiovas-
cular outcomes in OSA.
Some population studies have confirmed the results of
these clinical-based cohort studies. In a 18-year mortality
follow up conducted on the Wisconsin Sleep Cohort sam-
ple (n = 1522), the adjusted hazard ratio (95% CI) for
all-cause mortality with severe OSA (AHI > 30) versus no
OSA was 3.8 (1.6,9.0) irrespective of symptoms of sleepi-
ness [15]. The Busselton study confirms this finding in a
relatively young population in Australia [16], while in a
somewhat older population such as Sleep Health Heart
Study, the excess mortality associated with OSA was only
shown in men [17]. The problem with these three epi-
demiological studies is that the effect of OSA treatment
on health outcomes could not be adequately evaluated.
In addition with mortality, in cohort studies, OSA has
been linked with incident cardiovascular outcomes such
as hypertension [18], coronary artery disease [19],
Table 1 Long-term mortality studies in obstructive sleep apnea





Cohort studies published before 1996
He et al.; (Ref. #5) Retrospective 385 52 N. A AI > 20 has a RR mortality of 1.5 vs AI < 20 UPPP vs conservative: no
differences
Partinen et al.; (Ref. #6) Retrospective 198 56 5 years Tracheostomy vs conservative 5 years survival: 0% vs 6%
Bliwise et al.; (Ref. #7) Prospective 298 69 Up 12 years RR mortality for RDI > 10 of 2.67 (0.95–7.5, 95%CI).
Ancoli-Israel et al.; (Ref.
#8)
Prospective 233 83 3.3 years Significant association of AHI with death in women but not in men
Mant et al.; (Ref. #9) Prospective 163 83 4 years No relationship between RDI and survival
Lavie et al.; (Ref. #10) Prospective 1620 48 12 years Mortality OR of 1.012 for AI > 10 (not significant)
Cohort studies published after 1996
Lavie et al.; (Ref. #12) Prospective 13,850 48 4.5 years HR all-cause mortality, 2.2 for RDI > 30 (significant)
Yaggi et al. (Ref. #13) Prospective 1022 61 3.4 years HR all-cause mortality, 3.3 for AHI > 36 (significant)
Marin et al.; (Ref. # 14) Prospective 1651 50 10 years OR cardiovascular mortality, 2.87 for AHI > 30 (significant)
Young et al.; (Ref. #15) Prospective 1522 48 18 years HR all-cause mortality, 3.8 for AHI > 30 (significant)
Marshall et al.;(Ref. #16) Prospective 400 53 20 years HR all-cause mortality, 4.2 for RDI > 15 (significant)
Punjabi et al.; (Ref. #17) Prospective 6441 63 10 years HR all-cause mortality, 2.09 for AHI > 30 (in men aged 40–70 years)
Abbreviations: AI apnea index RR risk ratio, UPPP uvulopalatopharyngoplasty, AHI apnea-hipopnea index, RDI respiratory disturbance index, OD odds ratio, HR
hazard ratio, CVS cardiovascular, OSA obstructive sleep apnea
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myocardial infarction [20] and stroke [13]. Given the in-
creased cardiovascular morbidity and mortality in pa-
tients with OSA, the possibility that OSA was also a risk
factor for developing other cardiovascular risk factors
such as diabetes or dyslipidemia, has been investigated
in these cohort studies. A recent meta-analysis that in-
cludes a total of 64,101 participants reveals that OSA is
associated with incident diabetes, with an unadjusted
pooled relative risk of 1.62 (95% CI, 1.45–1.80) [21].
There are, however, no reports that have specifically ex-
plored the development of dyslipidemia in longitudinal
studies. Patients with OSA commonly experience mem-
ory problems, and neurocognitive disfunction [22], how-
ever, there are no data that allow associating OSA and
incident dementia. As part of the cognitive disfunction
and daytime sleepiness, it is well known that patients
with OSA are at higher risk for motor vehicle accidents
[23]. Finally, excess mortality in patients with OSA could
also be justified by an increased incidence of all types of
malignancies, especially in young adults with severe
OSA [24, 25].
Randomized studies
Long-term randomized controlled trials (RCTs) with the
aim of evaluating the effect of treatment on morbidity and
mortality in OSA are difficult to carry out due to the in-
surmountable ethical problems that supposed to stop
treating patients with significant diurnal symptoms. How-
ever, some RCTs have been carried out to assess the effect
of treatment on diurnal symptoms and quality of life dur-
ing relatively short time. Most studies have evaluated the
effect of CPAP on excessive daytime sleepiness (EDS) [26,
27] and health status [27]. Additionally, these studies im-
mediately showed that the positive effects of CPAP re-
quired a minimum effective use of more than 4 h a day.
As an alternative for patients intolerant to CPAP, man-
dibular advancement oral appliance therapy (MAT) can
be considered. Some short-term (3 months) RCT have
shown similar improvement in somnolence, vigilance,
and neurocognitive performance with MAT, compared
with CPAP in patients with mild-to-moderate OSA [28].
Upper airway surgery as a treatment option for OSA has
been extensively reviewed and meta-analyzed [29], how-
ever, until now, RCTs that have demonstrated their effi-
cacy on the symptomatology and quality of life of
patients with OSA have not been carried out.
Weight-loss intervention is effective to improve the
cardiovascular risk-factor profile in obese patients with
or without OSA. In addition, all bariatric surgery proce-
dures achieve improvement in their sleep apnea how-
ever, OSA can persist in after substantial weight loss [30]
so follow up sleep study needs to be done to determine
whether further OSA therapy is needed despite weight
loss. In RCT, the combined therapy of CPAP with
weight-loss intervention resulted in a larger reduction in
blood pressure than either CPAP or weight loss alone
[31]. There are no RCT head to head studies to compare
the effect of bariatric surgery versus CPAP, MAT or
other therapies.
Role of OSA in the evolution of other comorbid
diseases
Given that the majority of patients with OSA present
some comorbidity, especially cardiovascular or meta-
bolic, it is relevant to know how the most prevalent and
relevant comorbidities, mainly cardiovascular risk fac-
tors, will evolve depending on the treatment applied to
control apneas.
Hypertension
Arterial hypertension in patients with OSA should be
treated according to the current guidelines regardless of
the specific treatment that is to be applied for sleep
apnea. Nevertheless, three circumstances must be con-
sidered in the relationship hypertension - OSA.
A) In the normotensive patient with OSA who
consults for the first time, what is the future risk of
developing hypertension? Put it in another way, is
the treatment of OSA effective for the primary
prevention of hypertension? There are data that
suggest it. After considering confounding factors,
the odds of developing incident hypertension over
4 years in non-hypertensive OSA patients that re-
ceived no treatment, was threefold greater for those
with an AHI > 15 at baseline in population studies
[32], and twofold in clinical studies [33, 34] com-
pared with participants without OSA. However, in
the latter study, compared with controls, the
Table 2 Fully adjusted odds ratio for cardiovascular death
associated to clinical variables and diagnosis status
Variable Odds Ratio (95% Confidence
Interval)
P
Age, years 1.09 (1.04–1.12) 0.001
Diagnostic group
Snoring (AHI < 5) 1.03 (0.31–1.84) 0.88
Mild-moderate OSA (AHI: 5–
15)
1.15 (0.34–2.69) 0.71
Severe untreated OSA (AHI:
15–30)
2.87 (1.17–7.51) 0.025
OSA treated with CPAP (AHI:
> 15)
1.05 (0.39–2.21) 0.74
Prevalent CVS disease 2.54 (1.31–4.99) 0.005
Abbreviations: CPAP continuous positive airway pressure, CVS cardiovascular,
OSA obstructive sleep apnea, AHI apnea-hipopnea index. Adapted from Marin
JM, et al. (reference # 14)
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adjusted HRs for incident hypertension were greater
among patients with OSA ineligible for CPAP ther-
apy (1.33; 95% CI, 1.01–1.75), among those who de-
clined CPAP therapy (1.96; 95% CI, 1.44–2.66), and
among those nonadherent to CPAP therapy (1.78;
95% CI, 1.23–2.58), whereas the HR was lower in
patients with OSA who were treated with CPAP
therapy (0.71; 95% CI, 0.53–0.94) [33]. These results
were confirmed in a post hoc analysis of a RCT per-
formed during 4 years with normotensive patients
with OSA and without excessive daytime sleepiness.
In this multicentric study, CPAP treatment reduce
the incidence of hypertension or cardiovascular
events in patients with CPAP adherence of 4 h/
night or longer [35].
B) In patients with OSAS and associated hypertension,
how do the blood pressure (BP) figures in treated and
untreated subjects behave? This has been one of the
most studied topics of sleep medicine related to OSA.
From several recent RCTs and meta-analyzes, it can
be concluded that: in patients treated with CPAP that
show good compliance, diurnal systolic and diastolic
BP are reduced by an average of − 2.58mmHg (95%
CI, − 3.57 to − 1.59mmHg) and − 2.01 (95% CI, −
2.84 to − 1.18mmHg) compared to patients with un-
treated OSA. The effects were stronger in younger
and sleepier patients and more severe OSA [36]. It
should always be borne in mind that the reduction of
BP is a collateral effect of CPAP and that, this treat-
ment should not be used with the specific objective
of reducing the BP Figs.
C) In a patient with arterial hypertension, when should
the co-existence of OSA and its potential role in
the pathogenesis of hypertension be suspected?
Since more than 80% of OSA patients have a non-
dipping BP profiles in a sample of untreated pa-
tients with mild to severe OSA [37], hypertensive
subjects that demonstrate a BP drop < 10% of day-
time values (non-dippers) during a 24 h ambulatory
blood pressure monitoring (ABPM), should have a
sleep study to rule out OSA. These hypertensive
non-dippers are at higher risk of incident cardiovas-
cular events, and increased risk of renal disease pro-
gression as compared to nocturnal dippers [38].
Another very important group of hypertensive pa-
tients in whom a sleep study is needed to rule out
the coexistence of OSA are those with resistant
hypertension (RH) defined as an office BP ≥140/90
mmHg despite the use of 3 or more antihyperten-
sive agents [39]. In this subgroup, the prevalence of
OSA is reported to be 70–83% [40] and the treat-
ment with CPAP showed a favorable reduction of
BP in RCT [41]. In summary, since among hyper-
tensive patients there was a dose-dependent
reduction in blood pressure and incident cardiovas-
cular diseases [42], those patients with comorbid
OSA who receive effective treatment with CPAP
are also receiving a treatment that helps them
stabilize their blood pressure and reduce their car-
diovascular morbidity and mortality.
Diabetes
It is recognized that the prevalence of diabetes among pa-
tients with OSA is greater than that in the non-OSA popu-
lation, and exhaustive reviews of the relationship between
OSA and diabetes have recently been published [43]. On
the other hand, based on clinical and population-based ob-
servational cohort studies, patients with severe OSA (eg
AHI > 30), without initial diabetes mellitus (DM), are con-
sidered to have an increased risk of developing DM in the
future. [44, 45]. There is no information on the role played
by the long-term treatment of OSA in reducing or not the
risk of developing diabetes.
Conversely, in observational studies of diabetic sub-
jects with OSA, effective treatment of OSA tend to im-
prove indicators of glycemic status [46]. A recent
systematic review and meta-analysis concluded that
CPAP does not improve glycemic control measure as
HbA1c [47]. However, the studies reviewed included
mostly non-sleepy patients, were of short duration (12
to 24 weeks) and in most of them, the daily use of CPAP
was lower than 4 h. Again, the selection of patients with
OSA that are included in the RCTs, is in itself a bias that
does not reflect the reality of the patients we see in the
clinics on a daily basis. For example, it is known that the
effect of CPAP on glucose metabolism is more effective
when patients are drowsier [48]. The clinician must
manage their diabetic patients with OSA based on the
clinical guidelines and should focus primarily on weight
reduction. as a target treatment for both the manage-
ment of diabetes and OSA.
Dyslipidemia
Several observational studies [49] and a meta-regression
analysis [50] support the existence of a link between
OSA and dyslipidemia. No studies have been conducted
to establish whether the treatment or not of OSA is as-
sociated with a reduction in the risk of developing dys-
lipidemia in subjects without lipid alterations at baseline.
On the other hand, there are RCTs that have evaluated
the response of CPAP in terms of blood lipids in pa-
tients with OSA and dyslipidemia with mixed results
[51, 52]. Again, it should be emphasized that the results
of the RCTs do not exactly reflect the usual patient
attended at sleep clinics. For example, the improvement
of hypersomnolence could be associated with increased
physical activity and caloric output, which can also con-
tribute towards improving dyslipidemia. Therefore, it is
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difficult to identify in the context of an integral manage-
ment of the patient with OSA (e.g hygienic-dietetic mea-
sures, promotion of exercise, abstinence from tobacco
and alcohol, CPAP, upper-airway surgery, etc. ...), which
of the therapeutic measures on an individual basis is
more effective to improve the lipid profile and health
outcomes.
Cardiovascular diseases
The acute and chronic cardiovascular effects of sleep
apnea are well known and have been extensively studied
[53]. On the other hand, among patients with OSA, the
prevalence of diseases promoted by atherosclerosis (eg,
stroke, ischemic heart disease, aneurysms, etc.) is higher.
The evidence of an increased risk of cardiovascular mor-
bidity and mortality among patients with untreated OSA
is consistent but comes from long-term clinical and
population studies [14–17]. There are also epidemio-
logical studies that have indicated a reduction in cardio-
vascular risk in patients with OSA treated correctly with
CPAP or with tracheostomy [14, 54]. The development
of RCT studies that confirm a causal relationship will
not be possible for reasons indicated above. Based on
this evidence and in parallel with how we inform our
smokers, the doctor must communicate to their patient
with severe OSA the risk and potential benefit of the
treatment of their underlying disease.
Another different problem is the influence it has on
the clinical course of an already established cardiovascu-
lar disease (eg coronary atherosclerotic disease, stroke,
aneurysm), suffering from OSA as an associated morbid-
ity. In the cardiovascular literature it is well established
that treating, for example, hypertension or dyslipidemia
of a patient with established coronary disease will ultim-
ately reduce the likelihood of new cardiovascular events
(secondary prevention). The effect of treating OSA in
this type of patients is not so clear. RCTs done in pa-
tients recruited in cardiac clinics, mostly with already
cardiovascular or cerebrovascular events, did not show
an improving in morbi-mortality compared to those
treated with CPAP. Nevertheless, a significant improve-
ment was reported in daytime sleepiness, quality of life,
mood, and work productivity in patients who received
CPAP [55, 56]. From the practical point of view and
until we know the results of more RCT currently under-
way, we must act with patients with cardiovascular dis-
ease and suspected OSA, following the same strategy as
with the “non-cardiovascular” patients. That is, based on
a good sleep history, ordering the appropriate sleep
study and designing the personalized treatment for each
case based on the current guidelines. For our part, we
would add that the sleep studies in this type of patients
should always be “attended” to specify the dominant
type of breathing-sleep disorder (eg, obstructive apneas,
central apneas) and if positive pressure ventilation is
Fig. 2 Treatment algorithm for obstructive sleep apnea (OSA). This flow diagram shows a general approach to the management of patients with
suspected OSA. See Box 61–2 for the Epworth Sleepiness Scale. AHI, apnea-hypopnea index; PAP, positive airway pressure
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required, its titration should always be done manually in
a second sleep study.
The present strategy in the long-term
management of OSA
There is no worldwide consensus about the management
of OSA. Several scientific societies have clinical manage-
ment guidelines for the initial treatment of OSA [57–
59]. Figure 2 shows our strategy for the prescription of
CPAP. Currently sleep specialist are moving to treat their
patients from a mechanistic perspective grouping patient
into phenotypic traits that cause OSA such upper airway
anatomic compromise, high loop gain, low respiratory
arousal threshold and poor pharyngeal muscle responsive-
ness during sleep [60]. However, there is no specific recom-
mendation on how the patient’s long-term follow up
process should be, what specialist should initiate the pa-
tient’s diagnostic and therapeutic process, how often and
until when a patient’s course should be followed after being
diagnosed or when should a new sleep study be carried out.
In addition to an intervention to increase the upper air-
way lumen with pharyngeal surgery or to prevent the col-
lapsibility of the upper airway with the application of
CPAP, the management of OSA should always include
lifestyle intervention. A comprehensive lifestyle interven-
tion (CLI) program includes a reduced-calorie diet, exer-
cise/increased physical activity, and behavioral counseling.
A seminal RCT of a CLI demonstrated significant im-
provement in AHI parallel with weightloss [61]. CLI is
particularly effective in overweight and obese patients with
OSA. A CLI program that effectively achieves a weight re-
duction, not only improves the AHI, but simultaneously
impacts on the prognosis of a coexisting diabetes [62],
hypertension and cardiovascular diseases [63]. A recent
Clinical Practice Guideline document from the American
Thoracic Society summarizes the principles and recom-
mendations of CLI in the management of OSA [64].
The current trend is that any recommendation in-
cluded in the guidelines must be strictly evidence-based.
However, in many real-world situations, evidence is not
available. In our opinion, when irrefutable evidence is
lacking on certain aspects of clinical management, com-
mon sense and good practices should prevail. Some rec-
ommendations in the field of sleep-breathing disorders
should be implemented without the need for large ran-
domized trials. Indeed, there is no randomized trial sup-
porting the benefit of smoking cessation, yet it is
recommended in all guidelines. One of the responsibil-
ities of a physician is to interpret their patients’ individ-
ual problems. We have brought in our Sleep Clinic the
recommendations derived from scientific knowledge in
the area of OSA, and, following the worthy example of a
passage from the Old Testament that has served human-
ity for thousands of years, have set them down in 10
OSA commandments (Table 3). This simple guideline
constitutes an attractive, easy and practical approach to
the management of COPD in all its variations and will
give physicians the freedom to provide the best possible
care to their patients.
Conclusions
The current knowledge about the clinical course or nat-
ural history of the disease in the case of obstructive sleep
apnea, comes largely from the clinical experience of the
physicians who have handled this type of patients for de-
cades. In support of this knowledge, we only have some
clinical-base and populational observational studies. Un-
like other areas of medicine, in the case of OSA, we will
not be able to have large long-term RCTs that help us to
define the management of our patients. At present, the
initial treatment of patients with OSA should focus on
eliminating apneas with personalized therapy for each
subject with the ultimate goal of normalizing the quality
of life and control or delay the occurrence of comorbidi-
ties. To help achieve this goal, we must include the pa-
tient in lifestyle improvement programs with the
ultimate goal of reducing weight and increasing physical
activity, especially in overweight or obese subjects.
Abbreviations
ABPM: Ambulatory blood pressure monitoring; AHI: Apnea hypopnea index;
BMI: Body mass index; BP: Blood pressure; CPAP: Continuous positive airway
pressure; DM: Diabetes mellitus; MAT: Oral appliance therapy;
OSA: Obstructive sleep apnea; RCT: Randomized controlled trial;




Table 3 The 10 OSA Commandments®
Prevention I Help to avoid overweight and obesity
Diagnosis II Suspect OSA in cases of snoring and/or visualized
apneas or daytime sleepiness
III Confirm the diagnosis. Perform sleep study
IV Quantify sleepiness, BMI, AHI, and nocturnal hypoxemia
V Identified comorbidities, particularly cardiovascular,
metabolic and neurocognitive deficits
VI Explore the upper airway and look for treatable
anatomic abnormalities
Treatment VII Establishes a program to reduce weight
VIII Start patient-specific treatment
IX Supervise the correct use of CPAP and other devices
and medications
Follow-up X Establish a follow up plan and measure response to
treatment
Abbreviations: OSA obstructive sleep apnea, BMI body mass index, AHI apnea-
hipopnea index, CPAP continuous positive airway pressure
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